A recent clinical study attempting to treat T1D using low-dose IL-2 in combination with Treg found a significant effect on Treg function maintenance while also neglecting the amplification of NK or CD8 T cells, which may be ameliorated by modification of IL-2 in the future (31). This evidence concerns the gene IL2 and type 1 diabetes mellitus.